ENVISTA INTRAOCULAR LENS MX60P MX60P2050

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a foreign,health professional report with the FDA on 2020-03-24 for ENVISTA INTRAOCULAR LENS MX60P MX60P2050 manufactured by Bausch + Lomb.

Event Text Entries

[184828163] The device is not available for evaluation as it remains implanted. The viscoelastic eyefill c used are not validated for use with this lens. The lot history, trend analysis, risk analysis and directions for use review were considered acceptable, with the product performing within anticipated rates. No corrective action required. In the surgeon? S opinion, the likely cause of the event is inflammation due to the combined procedure and reduced compliance of patient to administer eye drops (steroids). Patient was non-compliant with preoperative anti glaucoma therapy and post-operative corticosteroid therapy. The most probable root cause is that this event is patient related.
Patient Sequence No: 1, Text Type: N, H10


[184828164] A user facility in germany reported a patient had a fibrin reaction to the intraocular lens (iol). The patient had a combined phacoemulsification and iol procedure and microshunt (santen) glaucoma procedure. The incision type was clear corneal. The incision was sutured at the time of the surgery (intraoperatively) but removed at the end of the surgery. There was no evidence or suspicion of a wound leak. The procedure was approximately between 15 to 30 minutes long without any complications. No discoloration noted postoperatively. 1-2 days after the surgery, the patient did not experience cloudiness. One week later, an ophthalmologist in the practice noted the cloudiness and referred the patient to the surgeon in the clinic. Three weeks post-surgery, there was suspicion of iol opacification. Slit lamp finding showed grey/opaque iol. Opacification on the front part of iol. It was reported the patient experienced loss of vision, patient? S bcva decreased 1/35. Approximately five weeks post-surgery, a yag-lens polish revealed membrane in the front of the iol surface (possibly inflammatory membrane). There was no opacity of the eye, but fibrin around the lens. With the yag laser, the opacity in front of the lens could be removed centrally, similar to a post-star laser treatment. A second iol polish was performed approximately one week later and a third treatment was performed one week after that. The patient is still undergoing evaluation. A follow up for refraction check was scheduled and the patient is to follow up with the glaucoma department.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number0001313525-2020-00060
MDR Report Key9870813
Report SourceFOREIGN,HEALTH PROFESSIONAL
Date Received2020-03-24
Date of Report2020-02-13
Date of Event2020-01-22
Report Date2005-01-01
Date Reported to FDA2005-01-01
Date Reported to Mfgr2005-01-10
Date Mfgr Received2020-03-05
Date Added to Maude2020-03-24
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactSTEPHANIE ANASTASIOU
Manufacturer Street21 N PARK PL BLVD.
Manufacturer CityCLEARWATER FL 33759
Manufacturer CountryUS
Manufacturer Postal33759
Manufacturer Phone7277246659
Single Use0
Previous Use Code0
Event Type3
Type of Report3

Device Sequence Number: 1

Brand NameENVISTA INTRAOCULAR LENS
Generic NameINTRAOCULAR LENS
Product CodeHQL
Date Received2020-03-24
Model NumberMX60P
Catalog NumberMX60P2050
Lot Number3967917
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device Sequence No1
Device Event Key0
ManufacturerBAUSCH + LOMB
Manufacturer AddressROCHESTER NY 14609 US 14609

Device Sequence Number: 101

Product Code---
Date Received2020-03-24
Device Sequence No101
Device Event Key0


Patients

Patient NumberTreatmentOutcomeDate
101. Required No Informationntervention 2020-03-24

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.